Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH-CD30: CD30.CAR T Cells in Relapsed Classical Hodgkin Lymphoma
NCT07575893Phase 1Not yet recruiting
- Sponsor
- New York Medical College
- Start
- Oct 2026
- Primary completion
- Dec 2031
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of ATLCAR.CD30 T cells in classical Hodgkin lymphoma (cHL), sponsored by New York Medical College. Primary endpoint: Recommended Phase 2 Dose at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ATLCAR.CD30 T cells
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT07575893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07575893.